Article Listing - Aricept and Aciphex boost Eisai results

DEPRESSION: THE COST TO SOCIETY

6 April 1992

The costs of depression to the National Health Service in the UK are L 333 million per year, according to...

ROBERTS PHARMA ACQUIRES NCRC

6 April 1992

The US concern Roberts Pharma-ceutical has reached a definitive agreement to acquire the National Clinical Research Centers in the USA...

GLAXO FRANCE CHIEF QUITS

6 April 1992

Edwin Nathan, president of Glaxo France and of the group's Belgian and Luxembourg companies, has announced his departure from the...

PROFITS UP AT ITALIAN SORIN BIOMEDICA IN 1991

6 April 1992

Sorin Biomedica made net profits in 1991 of 12.3 billion lire ($9.9 billion), up from 11 billion lire in the...

EPIC REGISTRATION NOW OVER 1,300

6 April 1992

Speaking at the 12th International Symposium on Intensive Care and Emergency Medicine in Brussels, late last month, Andre Heyns, Roussel-...

INTERFERON ALFA-N3 AND AIDS

6 April 1992

Researchers at the Walter Reed Army Institute of Research and at Interferon Sciences have commenced Phase I trials with the...

PA CONSULTING GROUP APPOINTMENTS

6 April 1992

Appointed as senior associates for the pharmaceutical industry at PA Consulting Group are Keith Mansford, former chairman of R&D...

WORLD MARKET FOR BIO-DRUGS

6 April 1992

Biopharmaceuticals will be the single fastest-growing segment of the total pharmaceutical market worldwide in the 1990s, with average annual growth...

TAMOXIFEN OF BENEFIT IN OSTEOPOROSIS?

6 April 1992

A US study looking at the effects of Imperial Chemical Industries' synthetic anti-estrogen Nolvadex (tamoxifen) in post-menopausal women with early-stage...

DRUGS AND SWEDEN'S HEALTH BILL

6 April 1992

Sales of pharmaceutical products in Sweden totaled 10 billion krone ($1.6 billion) in 1990, an increase of 1 billion krone...

Showing 94381-94390 of 95353 articles